CRON

Cronos Group (CRON) received an upgrade to Zacks Rank #1 (Strong Buy) based on upward revisions in earnings estimates. The cannabis company has seen analysts steadily raise estimates over the past three months, with consensus estimates increasing 200%. The upgrade positions CRON in the top 5% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals.

Cronos Group shares rose 17% over three months following better-than-expected Q2 2026 results, with first-half revenues up 49% to $98.2 million driven by Canadian market share gains and international expansion. However, the company faces challenges including potentially unsustainable margin improvements, an Israeli anti-dumping investigation, and intensifying European competition from rivals like Village Farms and Tilray. Analysts maintain a cautious stance with unchanged earnings estimates.

Cronos Group has completed its acquisition of CanAdelaar B.V., the largest cannabis company in the Netherlands' adult-use cannabis pilot program (Wietexperiment), for a base purchase price of €57.5 million plus contingent cash earnouts. The acquisition establishes Cronos as the market leader in Europe's largest adult-use cannabis market and enables the company to execute its borderless product strategy in the Netherlands with CanAdelaar's proven operational track record and leading market share.